keyword
MENU ▼
Read by QxMD icon Read
search

sirolimus

keyword
https://www.readbyqxmd.com/read/28544782/rationale-and-design-of-amphilimus-sirolimus-eluting-stents-versus-zotarolimus-eluting-stents-in-all-comers-requiring-percutaneous-coronary-intervention-recre8-a-multicenter-randomized-clinical-trial
#1
Rik Rozemeijer, Mèra Stein, Peter Frambach, Michiel Voskuil, Adriaan O Kraaijeveld, Ramón Rodríguez-Olivares, Leo Timmers, Bruno Pereira, Saskia Z Rittersma, Pierfrancesco Agostoni, Pieter A Doevendans, Pieter R Stella
BACKGROUND: Amphilimus sirolimus-eluting stents (A-SES) represent a novel elution technology in the current era of drug-eluting stents with promising results in patients with diabetes mellitus. At present no large trial has been designed to evaluate clinical outcomes of A-SES as compared to new-generation drug-eluting stents in unselected patients. Accordingly, we designed this trial to evaluate clinical noninferiority of A-SES as compared with zotarolimus-eluting stents (ZES) in a real-world, all-comers setting...
May 22, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28533049/long-term-effect-of-sirolimus-on-serum-vegf-d-levels-in-patients-with-lymphangioleiomyomatosis
#2
Angelo M Taveira-DaSilva, Amanda M Jones, Patricia Julien-Williams, Mario Stylianou, Joel Moss
BACKGROUND: Sirolimus reduces serum levels of VEGF-D, size of chylous effusions, lymphangioleiomyomas, and angiomyolipomas, and stabilizes lung function in patients with lymphangioleiomyomatosis. METHODS: To determine whether reductions in VEGF-D levels are sustained over time, and parallel changes in lung function and lymphatic disease, we evaluated 25 patients with lymphangioleiomyomatosis and measured VEGF-D levels, lung function and extent of lymphatic disease before and during sirolimus therapy RESULTS: Treatment with sirolimus stabilized FEV1 and DLCO over a period of 4...
May 19, 2017: Chest
https://www.readbyqxmd.com/read/28527768/randomized-comparison-of-absorb-bioresorbable-vascular-scaffold-and-mirage-microfiber-sirolimus-eluting-scaffold-using-multimodality-imaging
#3
Erhan Tenekecioglu, Patrick W Serruys, Yoshinobu Onuma, Ricardo Costa, Daniel Chamié, Yohei Sotomi, Ting-Bin Yu, Alexander Abizaid, Houng-Bang Liew, Teguh Santoso
OBJECTIVES: The primary objective of this study was to evaluate the safety and effectiveness of the Mirage bioresorbable microfiber sirolimus-eluting scaffold compared with the Absorb bioresorbable vascular scaffold in the treatment of stenotic target lesions located in native coronary arteries, ranging from ≥2.25 to ≤4.0 mm in diameter. Secondary objectives were to establish the medium-term safety, effectiveness, and performance of the Mirage device. BACKGROUND: The current generation of bioresorbable scaffolds has several limitations, such as thick square struts with large footprints that preclude their deep embedment into the vessel wall, resulting in protrusion into the lumen with microdisturbance of flow...
May 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28526601/model-based-precision-dosing-of-sirolimus-in-pediatric-patients-with-vascular-anomalies
#4
Tomoyuki Mizuno, Chie Emoto, Tsuyoshi Fukuda, Adrienne M Hammill, Denise M Adams, Alexander A Vinks
Sirolimus is the first drug to show efficacy in the treatment of patients with complicated vascular anomalies. The current study expands on the evolution of a PK model-based strategy for the precision dosing of sirolimus as part of prospective concentration controlled clinical trials in pediatric patients with vascular anomalies. Twelve month follow up data collected from 52 pediatric patients participating in the Phase 2 clinical trial were analyzed. Target attainment across the age range of 3weeks to 18years after 2-3months of therapy was 94% (49 out of 52 patients)...
May 16, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28512785/clinical-immunological-molecular-analyses-and-outcomes-of-iranian-patients-with-lrba-deficiency-a-longitudinal-study
#5
Gholamreza Azizi, Hassan Abolhassani, Seyed Alireza Mahdaviani, Zahra Chavoshzadeh, Peyman Eshghi, Reza Yazdani, Fatemeh Kiaee, Mohammadreza Shaghaghi, Javad Mohammadi, Nima Rezaei, Lennart Hammarström, Asghar Aghamohammadi
BACKGROUND: LPS-responsive beige-like anchor protein (LRBA) deficiency is a combined immunodeficiency caused by mutation in LRBA gene. The patients have a variety of clinical symptoms including hypogammaglobulinemia, recurrent infections, autoimmunity and enteropathy. METHODS: A total of 17 LRBA-deficient patients were enrolled in this longitudinal study. For all patients, demographic information, clinical records, laboratory and molecular data were collected. RESULTS: Hypogammaglobulinemia were reported in 14 (82...
May 17, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/28512069/optical-coherence-tomography-findings-insights-from-the-randomised-multicentre-trial-investigating-angiographic-outcomes-of-hybrid-sirolimus-eluting-stents-with-biodegradable-polymer-compared-with-everolimus-eluting-stents-with-durable-polymer-in-chronic-total
#6
Koen Teeuwen, Eva M Spoormans, Johan Bennett, Christophe Dubois, Walter Desmet, Giovanni J Ughi, Ann Belmans, Johannes C Kelder, Jan G P Tijssen, Pierfrancesco Agostoni, Maarten J Suttorp, Tom Adriaenssens
AIMS: The PRISON IV trial investigated the next-generation sirolimus-eluting stent (SES) with ultra-thin struts and biodegradable polymer against the second-generation everolimus-eluting stent (EES) with thin struts and durable polymer in patients with successfully recanalised chronic total occlusions (CTO). In this study, we examined the secondary optical coherence tomography endpoints. METHODS AND RESULTS: The main PRISON IV trial randomised 330 patients to either SES or EES...
May 18, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28507917/systemic-meta-analysis-assessing-the-short-term-applicability-of-early-conversion-to-mammalian-target-of-rapamycin-inhibitors-in-kidney-transplant
#7
Jayant Kumar, Isabella Reccia, Tomokazu Kusano, Bridson M Julie, Ajay Sharma, Ahmed Halawa
AIM: To consolidate the present evidence of effectiveness in renal functioning and graft survival following early introduction of mammalian target of rapamycin (mTOR) inhibitors with or without calcineurin inhibitors (CNIs) in renal transplant recipients. METHODS: We analysed the current literature following PROSPERO approval describing the role of immunosuppressive agent, mTOR inhibitors as an alternative to CNI within six months of renal transplant by searching the PubMed, EMBASE, Cochrane, Crossref, and Scopus using MeSH terms...
April 24, 2017: World Journal of Transplantation
https://www.readbyqxmd.com/read/28504218/first-in-human-evaluation-of-a-novel-poly-l-lactide-based-sirolimus-eluting-bioresorbable-vascular-scaffold-for-the-treatment-of-de-novo-native-coronary-artery-lesions-meres-1-trial
#8
Ashok Seth, Yoshinobu Onuma, Ricardo Costa, Praveen Chandra, Vinay K Bahl, Cholenahally N Manjunath, Ajaykumar U Mahajan, Viveka Kumar, Pravin K Goel, Gurpreet S Wander, Mathew S Kalarickal, Upendra Kaul, V K Ajit Kumar, Pratap C Rath, Vijay Trehan, Gunasekaran Sengottuvelu, Sundeep Mishra, Alexandre Abizaid, Patrick W Serruys
AIMS: The MeRes-1 trial sought to study the safety and effectiveness of a novel sirolimus-eluting bioresorbable vascular scaffold (MeRes100 BRS) in treating de novo native coronary artery lesions by clinical evaluation and using multiple imaging modalities. METHODS AND RESULTS: The MeRes-1 first-in-human trial was a single-arm, prospective, multicentre study, which enrolled 108 patients with de novo coronary artery lesions (116 scaffolds were deployed to treat 116 lesions in 108 patients)...
May 16, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28502378/long-term-treatment-of-cutaneous-manifestations-of-tuberous-sclerosis-complex-with-topical-1-sirolimus-cream-a-prospective-study-of-25-patients
#9
Nausicaa Malissen, Laurence Vergely, Marguerite Simon, Agathe Roubertie, Marie-Claire Malinge, Didier Bessis
BACKGROUND: Data on long-term topical sirolimus treatment of the cutaneous manifestations of tuberous sclerosis complex are rare. OBJECTIVE: To evaluate the long-term benefit and tolerance of topical 1% sirolimus in tuberous sclerosis complex. METHODS: In this 18-month prospective single-center study, 1% sirolimus cream was applied daily to facial angiofibromas (FAs), fibrous cephalic plaques (FCPs), shagreen patches, hypomelanotic macules, and ungual fibromas...
May 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28495897/geographical-difference-of-the-interaction-of-sex-with-treatment-strategy-in-patients-with-multivessel-disease-and-left-main-disease-a-meta-analysis-from-syntax-synergy-between-pci-with-taxus-and-cardiac-surgery-precombat-bypass-surgery-versus-angioplasty-using
#10
Yohei Sotomi, Yoshinobu Onuma, Rafael Cavalcante, Jung-Min Ahn, Cheol Whan Lee, David van Klaveren, Robbert J de Winter, Joanna J Wykrzykowska, Vasim Farooq, Marie-Claude Morice, Ewout W Steyerberg, Seung-Jung Park, Patrick W Serruys
BACKGROUND: The impact of sex on clinical outcomes of percutaneous coronary intervention and coronary artery bypass graft for patients with multivessel coronary disease and unprotected left main disease could be dissimilar between Western and Asian populations. METHODS AND RESULTS: To assess clinical outcomes after percutaneous coronary intervention or coronary artery bypass graft in women and men with multivessel coronary disease and unprotected left main disease, a pooled analysis (n=3280) was performed using the patient-level data from 3 large randomized trials: SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery), PRECOMBAT (Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease), and BEST (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease) trials...
May 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28491859/autophagy-in-kidney-transplants-of-sirolimus-treated-recipients
#11
Sagar Bhayana, Arpita Baisantry, Thomas D Kraemer, Christoph Wrede, Jan Hegermann, Jan-Hinrich Bräsen, Clemens Bockmeyer, Jan Ulrich Becker, Matthias Ochs, Wilfried Gwinner, Hermann Haller, Anette Melk, Roland Schmitt
BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are increasingly used as immunosuppressive agents in kidney transplantation. In the experimental setting it has been shown that mTOR inhibitors promote autophagy, but the concept that this might also occur in transplant patients has not been addressed. OBJECTIVES: This study was designed to investigate the association between mTOR inhibition and autophagy in renal transplants under routine clinical conditions...
March 2017: Journal of Nephropathology
https://www.readbyqxmd.com/read/28487969/applicability-of-electrospun-polypropylene-carbonate-polymers-as-a-drug-carrier-for-sirolimus
#12
Hourong Sun, Xinghua Gu, Kai Liu, Changcun Fang, Mengmeng Tang
Polypropylene carbonate (PPC), a biodegradable aliphatic polyester, exhibits one particular advantage over other polyesters, which is that following degradation in vivo, it primarily produces H2O and CO2, causing minimal side effects. Although PPC exhibits limited mechanical strength, and is therefore not able to serve as a scaffold to support tissue regeneration, it may be suitable for drug delivery; however, this requires further investigation. In the present study, electrospinning was applied to generate PPC polymers containing sirolimus, a cell growth‑inhibiting drug which is used to treat restenosis...
June 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28487033/incidence-and-long-term-clinical-impact-of-late-acquired-stent-fracture-after-sirolimus-eluting-stent-implantation-in-narrowed-coronary-arteries
#13
Shoichi Kuramitsu, Hiroyuki Jinnouchi, Tomohiro Shinozaki, Takashi Hiromasa, Yukiko Matsumura, Yuhei Yamaji, Mizuki Miura, Hiroaki Matsuda, Hisaki Masuda, Takenori Domei, Yoshimitsu Soga, Makoto Hyodo, Shinichi Shirai, Kenji Ando
The incidence and long-term clinical impact of stent fracture (SF) occurred beyond 1 year after sirolimus-eluting stent (SES) implantation remains unclear. From April 2004 to March 2008, 985 consecutive patients with 1,307 lesions were treated only with SES. Of these, 868 patients (88.1%) with 1,140 lesions underwent follow-up angiography within 1 year after the index procedure, and 646 patients (65.6%) with 872 lesions underwent it both within and beyond 1 year after the index procedure. According to the diagnosed timing of SF, we divided the patients into the 2 groups: early SF (<1 year after the index procedure) and late-acquired SF (>1 year after the index procedure)...
April 12, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28486787/sirolimus-for-the-treatment-of-progressive-kaposiform-hemangioendothelioma-a-multicenter-retrospective-study
#14
Yi Ji, Siyuan Chen, Bo Xiang, Kai Li, Zhicheng Xu, Wei Yao, Guoyan Lu, Xingtao Liu, Chuncao Xia, Qi Wang, Yanan Li, Chuan Wang, Kaiying Yang, Gang Yang, Xueyang Tang, Ting Xu, Hao Wu
Kaposiform hemangioendothelioma (KHE) is an aggressive disease with high morbidity and mortality. The aim of this study was to retrospectively evaluate the efficacy and safety of sirolimus for the treatment of progressive KHE. A multicenter, retrospective cohort study was conducted in patients with progressive KHE treated with sirolimus. A total of 52 patients were analyzed. Thirty-seven (71%) patients exhibited Kasabach-Merritt phenomenon (KMP) and were significantly younger than the patients without KMP (95% confidence interval [CI], 14...
May 9, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28484124/propensity-score-matched-comparison-of-midterm-angiographic-outcomes-of-sirolimus-versus-everolimus-and-biolimus-eluting-stents-for-de-novo-coronary-stenosis
#15
Kenichiro Suzuki, Tetsuya Ishikawa, Makoto Mutoh, Hiroshi Sakamoto, Chikara Mori, Takayuki Ogawa, Koichi Hashimoto, Takeyuki Kubota, Kimiaki Komukai, Michihiro Yoshimura
We conducted propensity-score matched comparisons of midterm angiographic outcomes of sirolimus (SES) versus either everolimus- (EES) or biolimus- (BES) eluting stents after placements for coronary stenosis in a daily practice environment since previous randomized trials did not demonstrate the superiority of EES and BES over SES in terms of midterm angiographic outcomes.The present study was a non-randomized, retrospective, and lesion-based study, recruiting angiographically followed-up lesions within 550 days after successful and elective SES (n = 1793), EES (n = 1303), or BES (n = 324) placement for de novo native coronary stenosis during the period from August 2004 to January 2014 at 6 institutes...
May 8, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28479418/development-of-an-assay-for-cellular-efflux-of-pharmaceutically-active-agents-and-its-relevance-to-understanding-drug-interactions
#16
Benigno C Valdez, Moustapha Hassan, Borje S Andersson
Drug interactions may dictate the failure or success of a treatment. Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to various types of drugs and it is of utmost importance to understand how these drugs interact. The pharmacokinetics of busulfan, melphalan and cyclophosphamide, commonly used drugs in HSCT, are known to be affected by a variety of drugs with differing molecular structures. We hypothesized that these structurally-unrelated drugs affect the transport of DNA alkylating agents...
May 4, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/28471065/novel-ultrahigh-molecular-weight-amorphous-plla-bioresorbable-coronary-scaffold-upsized-up-to-0-8-mm-beyond-nominal-diameter-an-oct-and-histopathology-study-in-porcine-coronary-artery-model
#17
Pawel Gasior, Yanping Cheng, Edward A Estrada, Jenn McGregor, Kamal Ramzipoor, Chang Lee, Gerard B Conditt, Serge D Rousselle, Juan F Granada, Grzegorz L Kaluza
OBJECTIVES: The aim of the study was to evaluate the biomechanical properties and healing pattern of novel sirolimus-eluting, ultrahigh molecular weight amorphous poly-L-lactic acid bioresorbable scaffolds (S-BRS) that have been postdilated by 0.55 and 0.8 mm beyond the nominal diameters within the pressure-diameter compliance chart range. BACKGROUND: Due to the inherent limitations of bioabsorbable polymeric materials, overexpansion/upsizing may be very limited for some BRS such as the benchmark Absorb BVS...
May 4, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28467998/neointimal-healing-evaluated-by-optical-coherence-tomography-after-drug-eluting-absorbable-metal-scaffold-implantation-in-de-novo-native-coronary-lesions-rationale-and-design-of-the-magmaris-oct-study
#18
Pasi Karjalainen, Tuomas Paana, Jussi Sia, Wail Nammas
OBJECTIVES: We sought to explore neointimal healing assessed by optical coherence tomography (OCT) following implantation of the Magmaris sirolimus-eluting absorbable metal scaffold. METHODS: The Magmaris-OCT is a prospective, multicenter, single-arm observational clinical study, intended to enrol 60 consecutive patients with up to 2 de novo native coronary lesions, each located in different major epicardial vessels, with a reference vessel diameter of 2.5-3.5 mm, and a maximum lesion length of 20 mm...
May 4, 2017: Cardiology
https://www.readbyqxmd.com/read/28465534/low-proportion-of-follicular-regulatory-t-cell-in-renal-transplant-patients-with-chronic-antibody-mediated-rejection
#19
Wen Chen, Jian Bai, Haiyan Huang, Lili Bi, Xiangrui Kong, Yu Gao, Yong Han, Li Xiao, Bingyi Shi
Follicular regulatory T (Tfr) cell can effectively regulate humoral immunity, but its function and mechanism in antibody-mediated rejection (AMR) after organ transplantation remains unclear. Here we detected follicular helper T (Tfh) cell subsets in 88 renal transplant patients with chronic renal allograft dysfunction (40 with AMR and 48 without AMR). The ratio of Tfr cells in renal graft tissues and peripheral blood of AMR patients significantly decreased, while the ratio of IL-21-producing Tfh cells (Tfh2 and Tfh17) significantly increased, compared to non-AMR patients...
May 2, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28454795/rationale-and-design-of-the-japan-usa-harmonized-assessment-by-randomized-multicenter-study-of-orbusneich-s-combo-stent-japan-usa-harmonee-assessment-of-a-novel-des-platform-for-percutaneous-coronary-revascularization-in-patients-with-ischemic-coronary-disease
#20
David F Kong, Shigeru Saito, Shigeru Nakamura, Roxana Mehran, Stephen M Rowland, Allison Handler, Hussein R Al-Khalidi, Mitchell W Krucoff
Tissue trauma associated with stent implantation continues to generate early thrombosis rates of 0.9% to 1.3% for both bare-metal and drug-eluting stent platforms. The Combo sirolimus-eluting stent combines an abluminal, bioabsorbable polymer with a luminal CD34+ antibody designed to capture endothelial progenitor cells. This article describes the design and methods of the HARMONEE trial (NCT02073565), which represents the first randomized controlled trial of the Combo design against a best-in-class contemporary everolimus-eluting stent...
May 2017: American Heart Journal
keyword
keyword
4707
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"